Thc Biomed Intl Stock Revenue

THCBF Stock  USD 0  0.00  0.00%   
THC Biomed Intl fundamentals help investors to digest information that contributes to THC Biomed's financial success or failures. It also enables traders to predict the movement of THC Pink Sheet. The fundamental analysis module provides a way to measure THC Biomed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to THC Biomed pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

THC Biomed Intl Company Revenue Analysis

THC Biomed's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current THC Biomed Revenue

    
  3.34 M  
Most of THC Biomed's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, THC Biomed Intl is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, THC Biomed Intl reported 3.34 M of revenue. This is 99.96% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 99.96% higher than that of the company.

THC Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses THC Biomed's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of THC Biomed could also be used in its relative valuation, which is a method of valuing THC Biomed by comparing valuation metrics of similar companies.
THC Biomed is currently under evaluation in revenue category among its peers.

THC Fundamentals

About THC Biomed Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze THC Biomed Intl's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of THC Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of THC Biomed Intl based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in THC Pink Sheet

THC Biomed financial ratios help investors to determine whether THC Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in THC with respect to the benefits of owning THC Biomed security.